MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
56.24
+0.23 (+0.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close56.01
Open56.23
Bid0.00 x 0
Ask0.00 x 0
Day's Range55.75 - 56.37
52 Week Range53.63 - 66.80
Volume22,580,659
Avg. Volume11,302,653
Market Cap153.223B
Beta0.85
PE Ratio (TTM)54.44
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.92 (3.43%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck lagging this year, but charts show it's poised for ...
    CNBC Videos6 days ago

    Merck lagging this year, but charts show it's poised for ...

    Carter Worth, Cornerstone Macro, discusses one lagging stock that could make a comeback.

  • Biopharma wins in Trump tax bill
    Yahoo Finance Video6 days ago

    Biopharma wins in Trump tax bill

    One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.

  • Merck CEO on business conditions in China
    CNBC Videos10 days ago

    Merck CEO on business conditions in China

    Merck Chairman and CEO Stefan Oschmann weighs in on the business environment in China and how that has affected the pharmaceutical industry.

  • Better Buy: Johnson & Johnson vs. Merck
    Motley Fool21 hours ago

    Better Buy: Johnson & Johnson vs. Merck

    J&J stock is up in 2017, while Merck is down. But could the roles be reversed in 2018 and beyond?

  • Merck's Keytruda Misses Primary End Point for Gastric Cancer
    Zacks2 days ago

    Merck's Keytruda Misses Primary End Point for Gastric Cancer

    Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.

  • Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
    Zacks2 days ago

    Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA

    Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.

  • Reuters3 days ago

    Merck's Keytruda fails pivotal gastric cancer trial

    Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer. The trial, which was testing the drug as a second-line treatment, also failed to prevent the cancer from progressing in patients whose tumors expressed the PD-LI protein, the company said. The U.S. regulator earlier this year approved Keytruda as a third-line treatment for gastric cancer patients, who showed no response to two or more prior lines of therapy.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey3 days ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
    Zacks5 days ago

    Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma

    Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.

  • Capital Cube5 days ago

    ETFs with exposure to Merck & Co., Inc. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merck & Co., Inc. Here are 5 ETFs with the largest exposure to MRK-US. Comparing the performance and risk of Merck & Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • 5 Blue-Chip Stocks to Buy in Mid-Turnaround
    InvestorPlace6 days ago

    5 Blue-Chip Stocks to Buy in Mid-Turnaround

    Blue-chip stocks are pushing higher again on Monday, as the combination of speculative excitement surrounding bitcoin mixes with the holiday spirit and seasonal tailwinds to keep prices marching higher.

  • Reuters6 days ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Reuters6 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.

  • Reuters6 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.

  • Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend
    Simply Wall St.8 days ago

    Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend

    Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...

  • GuruFocus.com10 days ago

    52-Week Company Lows

    Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International

  • Why 2017 Was a Year to Forget for Merck & Co. Inc.
    Motley Fool10 days ago

    Why 2017 Was a Year to Forget for Merck & Co. Inc.

    Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.

  • Reuters11 days ago

    Roche to seize leap-frog opportunity in lung cancer

    After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday.

  • These 3 Stocks Just Raised Their Dividends
    Motley Fool11 days ago

    These 3 Stocks Just Raised Their Dividends

    Shareholders of Walt Disney, Merck, and McCormick are getting some gifts in advance of the holiday season.

  • Top Analyst Reports for Home Depot, Boeing & Merck
    Zacks12 days ago

    Top Analyst Reports for Home Depot, Boeing & Merck

    Top Analyst Reports for Home Depot, Boeing & Merck

  • Investopedia12 days ago

    Biotech Stocks May See a New M&A Wave in 2018

    Struggling biotech giants could bolster their stocks in 2018 if they acquire smaller drug companies.

  • Market Realist12 days ago

    Analyst Recommendations for Merck & Co. in November 2017

    Wall Street analysts estimate Merck & Co.’s (MRK) top line to rise 1.1% to ~$40.2 billion in 2017. EPS (earnings per share) is expected to be $3.94 for 2017.

  • 3 Stocks That Cut Bigger Checks Than PepsiCo
    Motley Fool12 days ago

    3 Stocks That Cut Bigger Checks Than PepsiCo

    Pepsi is a fantastic business with a healthy dividend. But your quarterly check will be even larger if you invest in these three companies.